1.
Ann Card Anaesth
;
2016 Apr; 19(2): 214-216
Artigo
em Inglês
| IMSEAR
| ID: sea-177385
RESUMO
Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.